Nine trials (n=383) were included in the review: eight randomised controlled trials and one controlled trial. Sample sizes ranged from 10 to 70. Evidence was graded as high (one trial), medium (seven trials) and low (one trial) using the PEDro scale. Overall the strength of evidence was considered moderate.
Five trials (including three trials in post menopausal women) reported significant increases in bone density (0.4% to 10.2%) for WBVE at six to 12 months duration in comparison with placebo and weight-bearing regimes. One trial reported a decrease in secretion of calcium phosphate after three weeks WBVE. Three trials (including two trials in post menopausal women) reported no statistically significant differences between groups.
Six trials reported largest bone density increases in trabecular bone of the hip, back or proximal tibia. One trial reported the largest bone density increase in the cortical bone of the tibia.
No serious adverse events were reported. Minor adverse events in the WBVE groups included temporary itching and skin redness in the lower extremities, and knee pain after using WBVE in two overweight subjects (two trials).